As of the most recent data (June 2026), SBFMW shows a receivables of $4M. That compares with $3.6M in the prior-year period — up 12.5% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, SBFMW's receivables is now $4M (was $3.6M) — a 12.5% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Sunshine Biopharma- Warrants (15/02/2027) is outperforming or lagging.

Tracking SBFMW's receivables over time shows whether Sunshine Biopharma- Warrants (15/02/2027) is scaling, shrinking, or reshaping that part of the business. The current reading is $4M That compares with $3.6M in the prior-year period — up 12.5% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has Sunshine Biopharma- Warrants (15/02/2027)'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $4M) with ownership activity and broader fundamentals.

Sunshine Biopharma- Warrants (15/02/2027)'s receivables is $4M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.